Trial Profile
Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 17 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 17 Dec 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2017.